Genmab Reports Combination Therapy Was Well Tolerated
Genmab said petosemtamab plus pembrolizumab was well tolerated, with no new safety signals identified.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Genmab, AbbVie drug combo shows 51% lower risk of progression in lymphoma trial
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.